NovaDel adds two oral sprays to product pipeline

By Lisa Kerner

Charlotte, N.C., Sept. 13 - NovaDel Pharma Inc. added two products to its pipeline of oral spray drug development candidates: Tizanidine Oral Spray (formerly NVD 422) for spasticity and Ropinirole Oral Spray (formerly NVD 434) for Parkinson's disease.

"NovaDel's oral spray technology may be particularly applicable to drugs for the treatment of central nervous disease disorders where the oral spray's ability to overcome difficulty in swallowing tablets and achieving rapid onset of action could fulfill important unmet medical needs for patients," chief executive officer Jan Egberts said in a company news release.

The company expects both the Tizanidine and Ropinirole oral sprays to enter clinical trials in the first quarter of 2007.

NovaDel is an emerging specialty pharmaceutical company located in Flemington, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.